ArticleEJNMMI research2014

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.

David L Bushnell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.